Kenneth Blum, Abdalla Bowirrat, Eric R Braverman, Catherine Dennen, Foojan Zeine, Nicole Jafari, Keerthy Sunder, Panayotis K Thanos, David Baron, Debmayla Barh, Ashim Gupta, Debasis Bagchi, Mark S Gold, Rajendra D Badgaiyan
{"title":"Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?","authors":"Kenneth Blum, Abdalla Bowirrat, Eric R Braverman, Catherine Dennen, Foojan Zeine, Nicole Jafari, Keerthy Sunder, Panayotis K Thanos, David Baron, Debmayla Barh, Ashim Gupta, Debasis Bagchi, Mark S Gold, Rajendra D Badgaiyan","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>One important area for consideration especially in terms of combating the ongoing never ending opioid crisis, relates to novel newer assessments for all addictive behaviors both substance and non-substance behaviors (RDS). It is very important to identify early in one's life the possibility of, because of known DNA antecedents, the presence of pre-addiction. The development of the Genetic Addiction Risk Severity (GARS) test, Blum's group believes that this type of testing should be the \"standard of care\" following additional studies. Understandably that while polymorphisms in the Mu-Opioid receptor (MOR) is of real concern in terms of setting people up for predisposition to opioid dependence, the genetic and epigenetic status of dopaminergic function must be considered as well. While this sounds bold (which it is) the results should be protected by the G.I. N. A. law enacted in the USA in 2011. One avenue of further investigation, instead of providing powerful opioids for opioid dependence, is to seek out non-addictive alternatives. Accordingly, other non-addictive modalities including genetic guided KB220 (amino-acid-enkephalinase-N-acetylcysteine-NAD), non-invasive rTMS for psychiatry and pain, epigenetic remodeling, gene edits, non-invasive H-wave for pain management and enhanced functionality, brain spotting, cognitive behavioral therapy awarenesss integration therapy, NUCALM, trauma therapy, awareness tools, genograms, exercise, sports, fitness programs (one hour per day), light therapy and even laughing therapy as well as any other known modalities that can induce reward symmetry. While the short term use of opioids for opioid dependence to reduce harm is certainly acceptable, clinicians should consider a better long-term plan.</p>","PeriodicalId":72603,"journal":{"name":"Clinical and experimental psychology","volume":"9 2","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental psychology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
One important area for consideration especially in terms of combating the ongoing never ending opioid crisis, relates to novel newer assessments for all addictive behaviors both substance and non-substance behaviors (RDS). It is very important to identify early in one's life the possibility of, because of known DNA antecedents, the presence of pre-addiction. The development of the Genetic Addiction Risk Severity (GARS) test, Blum's group believes that this type of testing should be the "standard of care" following additional studies. Understandably that while polymorphisms in the Mu-Opioid receptor (MOR) is of real concern in terms of setting people up for predisposition to opioid dependence, the genetic and epigenetic status of dopaminergic function must be considered as well. While this sounds bold (which it is) the results should be protected by the G.I. N. A. law enacted in the USA in 2011. One avenue of further investigation, instead of providing powerful opioids for opioid dependence, is to seek out non-addictive alternatives. Accordingly, other non-addictive modalities including genetic guided KB220 (amino-acid-enkephalinase-N-acetylcysteine-NAD), non-invasive rTMS for psychiatry and pain, epigenetic remodeling, gene edits, non-invasive H-wave for pain management and enhanced functionality, brain spotting, cognitive behavioral therapy awarenesss integration therapy, NUCALM, trauma therapy, awareness tools, genograms, exercise, sports, fitness programs (one hour per day), light therapy and even laughing therapy as well as any other known modalities that can induce reward symmetry. While the short term use of opioids for opioid dependence to reduce harm is certainly acceptable, clinicians should consider a better long-term plan.
需要考虑的一个重要领域,尤其是在应对持续不绝的阿片类药物危机方面,与针对所有成瘾行为(包括药物和非药物行为)的新型评估有关。由于已知的 DNA 前因,在生命早期识别是否存在成瘾前兆非常重要。布卢姆的研究小组开发了遗传成瘾风险严重程度(GARS)测试,并认为在进行更多研究后,这种测试应成为 "护理标准"。可以理解的是,虽然缪-阿片受体(MOR)的多态性是人们对阿片依赖易感性的真正关注点,但多巴胺能功能的遗传和表观遗传状况也必须考虑在内。虽然这听起来很大胆(确实如此),但研究结果应受到美国 2011 年颁布的 G.I. N. A. 法的保护。进一步研究的一个途径是寻找非成瘾性替代品,而不是提供强效阿片类药物来治疗阿片类药物依赖。因此,其他非成瘾性方式包括基因引导的 KB220(氨基酸-脑啡肽酶-N-乙酰半胱氨酸-NAD)、用于精神病和疼痛的无创经颅磁刺激、表观遗传重塑、基因编辑、用于疼痛管理和增强功能的无创 H 波、脑斑、认知行为疗法、意识整合疗法、NUCALM、创伤疗法、意识工具、基因图、运动、体育、健身计划(每天一小时)、光疗、甚至笑疗以及任何其他可诱导奖赏对称的已知方式。短期使用阿片类药物治疗阿片类药物依赖以减少伤害当然是可以接受的,但临床医生应考虑更好的长期计划。